Hatzis, Christos <br/><br/>
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.  [electronic resource] 

 -  JAMA  May 2011 
 - 1873-81 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-3598 
<br/><br/><label>Standard No.: </label>10.1001/jama.2011.593  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Algorithms<br/>Anthracyclines--therapeutic use<br/>Antineoplastic Agents, Hormonal--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biopsy, Needle<br/>Breast Neoplasms--drug therapy<br/>Bridged-Ring Compounds--therapeutic use<br/>Disease-Free Survival<br/>Drug Resistance, Neoplasm<br/>Female<br/>Forecasting<br/>Gene Expression Profiling<br/>Genes, Neoplasm--genetics<br/>Genes, erbB-2<br/>Genomics<br/>Humans<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Recurrence, Local<br/>Oligonucleotide Array Sequence Analysis<br/>Predictive Value of Tests<br/>Prognosis<br/>Prospective Studies<br/>Receptors, Estrogen--analysis<br/>Risk<br/>Taxoids--therapeutic use